Skip to main content

Haemonetics Corp(HAE-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low59.53
Day High61.48
Open:59.71
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
BTIG Reaffirms Their Buy Rating on Haemonetics (HAE)
StockStory
1 Value Stock on Our Buy List and 2 Facing Headwinds
HAE
StockStory
3 Small-Cap Stocks That Fall Short
WERN
Motley Fool
What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year
StockStory
2 Healthcare Stocks with Solid Fundamentals and 1 Facing Challenges
HAE
StockStory
A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q4 Earnings: Haemonetics (NYSE:HAE) Vs The Rest Of The Pack
HAE
Tipranks
Haemonetics Retires 2026 Convertible Notes, Simplifies Capital Structure
StockStory
3 Reasons HAE is Risky and 1 Stock to Buy Instead
HAE
StockStory
3 Profitable Stocks with Open Questions
GPC
Tipranks
Haemonetics (HAE) Gets a Buy from BTIG
Tipranks
Haemonetics Releases 2024-2025 Corporate Responsibility Report
StockStory
5 Revealing Analyst Questions From Haemonetics’s Q4 Earnings Call
HAE
Tipranks
Haemonetics Earnings Call: Strong Core, IVT Drag
Tipranks
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Haemonetics (HAE) and Denali Therapeutics (DNLI)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Haemonetics (HAE) and Ocular Therapeutix (OCUL)
StockStory
HAE Q4 Deep Dive: Plasma Momentum and Hospital Weakness Shape Mixed Results
HAE
Motley Fool
Haemonetics HAE Q3 2026 Earnings Call Transcript
StockStory
Haemonetics’s (NYSE:HAE) Q4 CY2025 Sales Top Estimates, Stock Soars
HAE
StockStory
What To Expect From Haemonetics’s (HAE) Q4 Earnings
HAE
Tipranks
Haemonetics (HAE) Receives a Buy from Barrington
StockStory
Reflecting On Medical Devices & Supplies - Specialty Stocks’ Q3 Earnings: Haemonetics (NYSE:HAE)
HAE
StockStory
1 Russell 2000 Stock to Keep an Eye On and 2 Facing Headwinds
HAIN
StockStory
3 Value Stocks with Open Questions
F
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Dianthus Therapeutics (DNTH), Eli Lilly & Co (LLY) and Haemonetics (HAE)
StockStory
1 Cash-Producing Stock Worth Your Attention and 2 Facing Challenges
BELFA
Tipranks
Haemonetics price target raised to $93 from $90 at Barrington
GlobeNewswire
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cartesian Therapeutics (RNAC), Rani Therapeutics Holdings (RANI) and Haemonetics (HAE)
Tipranks
Haemonetics acquires Vivasure to expand structural heart portfolio
StockStory
1 Small-Cap Stock Worth Your Attention and 2 We Avoid
HAE
StockStory
3 Low-Volatility Stocks We Think Twice About
CDRE
StockStory
Why Haemonetics (HAE) Shares Are Trading Lower Today
HAE

Profile

Haemonetics Corp. provides blood management solutions to customers encompassing blood and plasma collectors, hospitals and health care providers globally. Its portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood supply chain, helping better clinical outcomes. It acquired Pall Corporation's blood collection, filtration and processing product lines. It entered into a long-term supply agreement with Pall. The company acquired Hemerus Medical. It operates under 3 segments: Plasma, Blood Center, and Hospital. Plasma includes plasma collection devices and disposables, plasma donor management software, anticoagulant and saline sold to plasma customers. Blood Center includes blood collection and processing devices and disposables for red cells, platelets and whole blood as well as related donor management software. Hospital includes three product lines, namely, Hemostasis Management, Cell Salvage and Transfusion Management.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.